AR and prostate carcinoma: We established a CBZ-resistant AR-positive prostate cancer model, LNKO6CR, which was derived by incubating LNCaP under androgen ablation conditions for 6 months [23] and subsequently incubating with gradually increasing CBZ concentrations for 12 months (Supplementary Fig. 4A).